|
It
is a time of unprecedented scientific opportunity in
pharmaceutical research. The industry is in the midst
of revolutionary technological improvements and profound
scientific insights, leading to reinvention of the drug
discovery and development process.
The
advances in genomics, molecular science, information
technology, chemoinformatics, combinatorial chemistry,
robotics, and many other areas have collectively created
platforms which are expected to spawn innovations in
drug discovery and development. Many companies are increasingly
applying in-house-developed drug delivery technologies
to the pharmaceutical products of other drug makers
(New Drug Delivery Systems). Novel drug delivery systems
have been able to reduce attrition, make good drugs
better, extend profitable lifetime with second generation
drugs and reposition new drugs into optimal delivery
channels.
Despite
the said advances in science, out of every 5,000 molecules
tested, only five on average are tested in clinical
trials, according to the Pharmaceutical Research and
Manufacturers of America. Based on research by the Tufts
Centre for the Study of Drug Development, only one of
these five is eventually approved for patient use. |
